Clinical challenge: uncertainty in discharge and admission decisions for women at risk of preeclampsia - PreFree: the first CE-marked, multimodal prediction model for preeclampsia (biomarkers + ...
Through this engagement, Daré will provide strategic mentorship, technical guidance, and tailored project management support ...
14d
Daré Bioscience, Inc.: Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real ...
In low and middle-income countries such as Brazil, most maternal deaths are related to hypertensive complications. Preeclampsia is the leading cause of maternal mortality and morbidity. Significant ...
Presented at the New England Postgraduate Assembly, Cambridge, Massachusetts, November 13, 1940. From the Department of Obstetrics and Gynecology, the University of Chicago and the Chicago Lying-in ...
Preeclampsia Market Outlook 2025-2035: The preeclampsia market reached a value of USD 724.3 Million in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 873.0 Million by ...
Objectives Pre-eclampsia causes significant maternal and perinatal morbidity and mortality. It also causes changes in the cardiovascular, endothelial and metabolic systems, from which women may not ...
Preeclampsia is a multisystem hypertensive disorder that manifests itself after 20 weeks of pregnancy, along with proteinuria. The pathophysiology of preeclampsia is incompletely understood.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback